Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.

Gilgun-Sherki Y, Eliaz RE, McCann DJ, Loupe PS, Eyal E, Blatt K, Cohen-Barak O, Hallak H, Chiang N, Gyaw S.

Drug Alcohol Depend. 2016 Sep 1;166:13-20. doi: 10.1016/j.drugalcdep.2016.05.019. Epub 2016 May 28.

2.

Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.

Tolmasov M, Djaldetti R, Lev N, Gilgun-Sherki Y.

Expert Rev Neurother. 2016 May;16(5):505-13. doi: 10.1586/14737175.2016.1164600. Epub 2016 Mar 25. Review.

PMID:
26959397
4.

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y.

Expert Rev Neurother. 2015 Jun;15(6):575-86. doi: 10.1586/14737175.2015.1040768. Epub 2015 Apr 30. Review.

PMID:
25924547
5.

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects.

Cohen-Barak O, Wildeman J, van de Wetering J, Hettinga J, Schuilenga-Hut P, Gross A, Clark S, Bassan M, Gilgun-Sherki Y, Mendzelevski B, Spiegelstein O.

J Clin Pharmacol. 2015 May;55(5):573-83. doi: 10.1002/jcph.450. Epub 2015 Jan 12.

6.

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, Correia de Sá J, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.

J Neurol. 2015 Jan;262(1):248. doi: 10.1007/s00415-014-7565-7. No abstract available.

7.

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.

J Neurol. 2014 Nov;261(11):2101-11. doi: 10.1007/s00415-014-7446-0. Epub 2014 Aug 14. Erratum in: J Neurol. 2015 Jan;262(1):248.

8.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group.

J Neurol. 2014 Apr;261(4):773-83. doi: 10.1007/s00415-014-7264-4. Epub 2014 Feb 18.

PMID:
24535134
9.

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group.

Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: Lancet. 2010 Apr 24;375(9724):1436.

PMID:
19815268
10.

Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.

Gilgun-Sherki Y, Melamed E, Offen D.

Curr Pharm Des. 2006;12(27):3509-19. Review.

PMID:
17017944
11.

A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.

Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D.

Clin Neuropharmacol. 2005 Nov-Dec;28(6):285-8.

PMID:
16340385
12.
13.

Therapeutic potential of neurotrophic factors in neurodegenerative diseases.

Levy YS, Gilgun-Sherki Y, Melamed E, Offen D.

BioDrugs. 2005;19(2):97-127. Review.

PMID:
15807629
14.

A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.

Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E.

Eur J Neurosci. 2005 Feb;21(3):637-46.

PMID:
15733082
15.

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.

Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D.

Pharmacogenomics J. 2004;4(5):291-306. Review.

PMID:
15224083
16.

A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis.

Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D.

J Neurochem. 2004 Jun;89(5):1241-51.

17.

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.

Gilgun-Sherki Y, Melamed E, Offen D.

J Neurol. 2004 Mar;251(3):261-8. Review.

PMID:
15015004
18.

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.

Gilgun-Sherki Y, Panet H, Melamed E, Offen D.

Brain Res. 2003 Nov 7;989(2):196-204.

PMID:
14556941
19.

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis.

Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D.

Neurosci Res. 2003 Oct;47(2):201-7.

PMID:
14512144
20.

Antioxidant treatment in Alzheimer's disease: current state.

Gilgun-Sherki Y, Melamed E, Offen D.

J Mol Neurosci. 2003;21(1):1-11. Review.

PMID:
14500988

Supplemental Content

Loading ...
Support Center